MyoKardia

$52.95
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$1.76 (-3.21%) As of 1:59 PM EDT today
-$1.76 (-3.21%) Today

Why Robinhood?

You can buy or sell MyoKardia and other stocks, options, ETFs, and crypto commission-free!

About MYOK

MyoKardia, Inc. operates as a biopharmaceutical company. It engages in the discovery, development, and commercialization of targeted therapies for the treatment of cardiovascular diseases. Read More The firm focuses on the treatment of heritable cardiomyopathies, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. It offers MYK-46, an orally-administered small molecule designed to reduce excessive cardiac muscle contractility to hypertrophic cardiomyopathy. The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in San Francisco, CA.

Employees
165
Headquarters
San Francisco, California
Founded
2012
Market Cap
2.52B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
279.89K
High Today
$54.60
Low Today
$52.04
Open Price
$53.81
Volume
159.91K
52 Week High
$67.79
52 Week Low
$39.01

Collections

MYOK News

ReutersAug 8

Edited Transcript of MYOK earnings conference call or presentation 7-Aug-19 8:30pm GMT

1

MYOK Earnings

-$0.93
-$0.68
-$0.44
-$0.19
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Estimated
Actual
Expected Nov 6

More MYOK News

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.